The purpose of this study is to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with recent Acute Coronary Syndrome (ACS)
Contact phone
517-364-5760
Contact email
[email protected]
Principal investigator
Dr. Chad Link, DO
Trial Category
Heart & Vascular
Trial SubCategory
Cardiovascular Disease
Webform